Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
about
Optimal lipid modification: the rationale for combination therapyFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewFenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats.Micronized fenofibrate: a new fibric acid hypolipidemic agent.Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus.Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanismPPARα in Obesity: Sex Difference and Estrogen Involvement.Emerging drugs for hyperlipidemia.Evaluation and management of dyslipidemia in patients with HIV infection.Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk.Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.Fibrates and cholestasisCombination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.Update on the use of fibrates: focus on bezafibrateGenomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout.Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Gemfibrozil-induced myositis in a patient with normal renal function.Pharmacotherapy of dyslipidemias in the adult population.Do persons with diabetes benefit from combination statin and fibrate therapy?The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box?Expression pattern of L-FABP gene in different tissues and its regulation of fat metabolism-related genes in duck.Ezetimibe: a novel option for lowering cholesterol.Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus GJapan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
P2860
Q28219266-2AEA38A5-CD8E-4118-9CD6-46A82F3BD400Q28220294-3615C555-8DD7-449C-803D-F4061743AD35Q32065269-22F58701-3C36-47A7-99CF-6337D85DC821Q33759380-3BA90BEA-33FF-4ECA-85C2-198259724BC6Q33915449-33D71A3A-8C01-4B11-9F1B-75C080207141Q33931073-1D9C373F-6503-499B-A3F9-0FFEECFCC062Q34143769-002E457F-BACC-40F9-846B-DEB4009FBEFEQ34619115-0D081F1D-D736-44C9-A726-893A125F96F0Q34743413-3DF0BB51-0B06-461C-9763-F7F00D002A73Q34975672-7BA3EA5D-C5AA-4418-A907-D197F49F7EC2Q35595343-0D483542-0012-469C-AF11-28DF63C799E5Q35889448-34517E57-FC92-4882-8888-9EA9F1A1445CQ36569771-79489828-A240-4D81-AC0C-0C9BC44E892DQ36766923-56912C91-185E-4DE2-A50F-092362BD1F00Q36838204-3719267A-6E4F-4F7E-B2A2-FBCEF49DEF07Q36847314-8F29588C-0988-40E4-B9BA-7704F08001CEQ37577126-057B6835-ED7F-4CA4-A046-4BF36A00A075Q37637746-6E47C8B6-D0C8-4EF7-B9D0-C8E6C29DBB90Q37801374-5A407AF3-88DD-4CA8-AAF5-ADBF2534CF7FQ37972824-3A65F5B5-0A4E-4D66-9EAF-EA00C9B3EB3EQ38273378-BA859B68-9480-414C-9284-54964DBF31E8Q43986735-A351900F-04BF-47A6-BCCD-C4572AD276D4Q44582581-B269CE65-6631-4600-9199-CF58E7E56DA8Q44804875-59ACC25B-9D4F-48EA-9C8D-5491BC92F35CQ45739775-4EFAF478-4D88-40F9-B105-91C36749B5A3Q58362346-5376CE55-8156-45C7-BE7F-FA4C51493917
P2860
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Consensus for the use of fibra ...... ease. Fibrate Consensus Group.
@en
type
label
Consensus for the use of fibra ...... ease. Fibrate Consensus Group.
@en
prefLabel
Consensus for the use of fibra ...... ease. Fibrate Consensus Group.
@en
P2093
P1476
Consensus for the use of fibra ...... ease. Fibrate Consensus Group.
@en
P2093
Brewer HB Jr
Fruchart JC
Leitersdorf E
P304
P356
10.1016/S0002-9149(98)00010-1
P407
P577
1998-04-01T00:00:00Z